PAVmed (PAVM) Stock Price, News & Analysis

Company Overview

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.58 to $0.61
• 50-Day Range: $0.58 to $0.82
• 52-Week Range: $0.55 to $1.90
• Volume: 78,158 shs
• Average Volume: 135,844 shs
• Market Capitalization: $10.08 million
• P/E Ratio: 0.83
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Buy

PAVmed Stock Analysis - MarketRank™

PAVmed scored higher than 78% of companies evaluated by MarketBeat, and ranked 209th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

PAVmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PAVmed has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PAVmed are expected to grow in the coming year, from ($3.56) to ($2.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PAVmed is 0.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.87.

Price to Earnings Ratio vs. Sector

The P/E ratio of PAVmed is 0.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.22.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.42% of the float of PAVmed has been sold short.

Short Interest Ratio / Days to Cover

PAVmed has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PAVmed has recently decreased by 7.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PAVmed does not currently pay a dividend.

Dividend Growth

PAVmed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

2.42% of the float of PAVmed has been sold short.

Short Interest Ratio / Days to Cover

PAVmed has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PAVmed has recently decreased by 7.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PAVmed insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of PAVmed is held by insiders.

Percentage Held by Institutions

Only 19.93% of the stock of PAVmed is held by institutions.

PAVM Stock Analysis - Frequently Asked Questions

How have PAVM shares performed this year?

PAVmed's stock was trading at $0.6275 at the beginning of the year. Since then, PAVM stock has decreased by 6.0% and is now trading at $0.59.

How were PAVmed's earnings last quarter?

PAVmed Inc. (NASDAQ:PAVM) released its earnings results on Thursday, August, 12th. The company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.50) by $0.60.
Read the conference call transcript.

When did PAVmed's stock split?

PAVmed's stock reverse split on Thursday, December 7th 2023.The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of PAVmed?

Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PAVmed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PAVmed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Pfizer (PFE).

Company Calendar

• Last Earnings: 8/12/2021
• Today: 7/07/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PAVM
• CIK: 1624326
• Web: www.pavmed.com
• Phone: (212) 949-4319
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $19.00
• High Stock Price Target: $19.00
• Low Stock Price Target: $19.00
• Potential Upside/Downside: +3,120.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.71
• Trailing P/E Ratio: 0.83
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $39.79 million
• Net Margins: 3,711.54%
• Pretax Margin: 3,289.61%
• Return on Equity: N/A
• Return on Assets: -42.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.37
• Quick Ratio: 0.37

Sales & Book Value

• Annual Sales: $2.99 million
• Price / Sales: 3.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.92) per share
• Price / Book: -0.64

Miscellaneous

• Outstanding Shares: 17,090,000
• Free Float: 15,845,000
• Market Cap: $10.08 million
• Optionable: Optionable
• Beta: 1.06